Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2025Frontiers in ImmunologyOpen Access

Targeting the epigenome and tumor heterogeneity: advances in immunotherapy for chemoresistant metastatic colorectal cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

NBNarasimha M. BeerakaSESergey EfetovAOAkmalbek A. Otabekov

Discussion

Loading...

Member takes

Overview

Review uncovers mitoepigenetic mechanisms and tumor heterogeneity, suggesting novel immunotherapy strategies for improving outcomes in metastatic CRC.

Key Points

  • Therapeutic strategies involving immunotherapy show potential for overcoming chemoresistance in colorectal cancer.
  • Key findings indicate that dysregulated epigenome and mitochondrial functions drive tumor progression in CRC.
  • Assessment of mitoepigenetic mechanisms reveals their role in colorectal cancer and may open avenues for targeted therapies.
  • Histone-modifying enzymes act as pivotal drivers of tumorigenesis, highlighting a promising direction for CRC treatment.

Cite This Study

Beeraka et al. (2025) studied this question.

synapsesocial.com/papers/694027692d562116f29002f3https://doi.org/10.3389/fimmu.2025.1623117
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An enhanced MITOMAP with a global mtDNA mutational phylogeny2006 · 679 citations
  2. 2Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma2025 · 14 citations
  3. 3Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q212008 · 606 citations
  4. 4Nonsense and missense mutation of mitochondrial ND6 gene promotes cell migration and invasion in human lung adenocarcinoma2015 · 68 citations
  5. 5Is cumulative frequency of mitochondrial DNA variants a biomarker for colorectal tumor progression?2004 · 27 citations